Question 1

Am I eligible for this trial based on my cancer type and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 clinical trial (NCT06767514). Contact the study team or your healthcare provider for specific answers.

Question 2

How does ivonescimab compare to pembrolizumab in terms of side effects and effectiveness?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 clinical trial (NCT06767514). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential risks and benefits of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 clinical trial (NCT06767514). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatments and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 clinical trial (NCT06767514). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 clinical trial (NCT06767514). Contact the study team or your healthcare provider for specific answers.

Question 6

Will my participation in this trial affect my ability to receive other treatments in the future?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 clinical trial (NCT06767514). Contact the study team or your healthcare provider for specific answers.

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

What this study is about

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

What this study is about